Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 7, 1998, Pages 355-362

  Harder, S ^a   Baas, H ^a   Demisch, L ^a   Simon, E ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apomorphine; Dopamine agonist; Parkinson's disease; PK PD model

Indexed keywords

APOMORPHINE;

AKINESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERANCE; HUMAN; MOTOR ACTIVITY; PARKINSON DISEASE; PHARMACODYNAMICS; RATING SCALE; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; APOMORPHINE; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE;

EID: 0031927819     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Baas H, Stecker K, Fischer PA 1993 Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's diesease. J Neural Transm Sect 5: 45-61
2. Bianchi G, Landi M 1985 Determination of apomorphine in rat plasma and brain by HPLC with electrochemical detection. J Chromatogr 338: 230-235
3. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A 1993 Pharmacodynamic modeling of oral levodopa. Neurology 43: 367-371
4. Durif F, Jeanneau E, Serre-Debeauvais D, Deffond D, Eschgalier A, Tournilhac M 1991 Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease. Eur J Clin Pharmacol 41: 493-494
5. Gancher ST, Nutt JG, Woodward WR 1992 Time course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 52: 504-510
6. Gancher ST, Woodward WR, Boucher B, Nutt JG 1989 Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 26: 232-238
7. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH 1992 Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 49: 1131-1134
8. Grandas F 1992 Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease. Neurology 42: 1287-1290
9. Grandas F, Obeso JA 1989 Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin Neuropharmacol 12: 14-22
10. Harder S, Baas H, Bürcklin F, Demisch L 1995b PK-PD relationship of levodopa alone and under apomorphine in patients with Parkinsons's disease. Clin Pharmacol Ther 57: 145
11. Harder S, Baas H, Rietbrock S 1995a Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 29: 243-256
12. Hoehn MM, Yahr MD 1967 Parkinsonism: onset, progression, and mortality. Neurology 4: 427-442
13. Hofstee DJ, Neef C, van Laar T, Jansen EN 1994 Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 17: 45-52
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ 1992 Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
15. Hughes AJ, Lees AJ, Stern GM 1991 The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 54: 358-360
16. Linazasoro G 1996 The apomorphine test in gait disorders associated with parkinsonism. Clin Neuropharmacol 19: 171-176
17. Maggio R, Barbier P, Corsini G 1995 Apomorphine continouus stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. J Neural Transm 45 (Suppl): 133-136
18. Montastruc JL, Rascol O, Senard JM 1993 Current status of dopamine agonists in Parkinson's disease management. Drugs 46: 384-393
19. Montgomery GK, Reynolds NC, Warren RM 1985 Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 8: 83-92
20. Ostergaard L, Werdelin L, Odin P et al 1995 Pen-injected apomorphine against off phenomena in late Parkinson's disease: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 58: 681-687
21. Poewe W, Kleedorfer B, Gerstenbrand F, Oertel WH 1989 Die Behandlung von Parkinsonpatienten mit L-Dopa-Wirkungsfluktuation mittels subkutanen Apomorphingaben. Aktuelle Neurologie 16: 73-77
22. Przedborski S, Levivier M, Raftopoulos C, Naini AB, Hildebrand J 1995 Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Move Dis 10: 28-36
23. Quinn NP, Ilias A, Lhermitte F, Agid Y 1981 Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology 31: 662-667
24. Sage JI, Mark MH 1994 Basic mechanisms of motor fluctuations. Neurology 44 (Suppl 6): S10-S14
25. Seeman P, Grigoriadis D 1987 Dopamine receptors in brain and periphery. J Neurochem Int 1: 1-25
26. Stibe CMH, Lees AJ, Kempster PA, Stern GM 1989 Subcutanous apomorphine in parkinsonian on-off oscillations. Lancet i: 403-406
27. Turjanski N, Fernandez W, Lees AJ 1993 The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 56: 771-775
28. Verotta D, Beal SL, Sheiner LB 1989 Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol 25: 1005-1010
29. Wachtel H 1991 Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transmission 3: 151-201